News Letter Highlights Invest NI’s Support for CV6’s Cancer Research
In November 2022, the News Letter reported on Invest Northern Ireland’s offer of £3 million in research and development grant support for CV6 Therapeutics’ cancer drug development project. The article highlights the funding and collaboration with Queen’s University Belfast supporting CV6-168’s preparations for its first human clinical trial, alongside plans to create four additional research roles.
Mel Chittock, then Interim Chief Executive of Invest Northern Ireland, described CV6-168 as “one of the first Northern Ireland developed drugs to be trialled here” and said the project would strengthen the region’s profile in cancer drug development.
Read the full article in the News Letter.
Pictured above are: Sir Ian Greer, Dr. Robert Ladner and Dr. Mel Chittock.
More News
View all
The Irish Times Reports on CV6’s Cancer Drug Development
Investment in CV6-168’s development and plans to expand the Belfast research team feature in coverage of the company’s preparations for human trials.
FirstWord Pharma Publishes CV6’s Clinical Development Funding Announcement
CV6’s November 2022 announcement outlined funding to advance CV6-168 toward its first human clinical trial and support further scientific development.